Literature DB >> 12009391

Troglitazone: a possible modulator of ovarian steroidogenesis.

Mohamed F M Mitwally1, Selma F Witchel, Robert F Casper.   

Abstract

OBJECTIVE: Troglitazone increases insulin sensitivity. When used to treat women with insulin-resistant polycystic ovary syndrome (PCOS), troglitazone lowers androgen concentrations and improves ovulatory, endocrine, and metabolic disturbances. However, it is not known whether these effects are due to increased peripheral insulin sensitivity only or to direct effects on steroidogenesis. To determine whether troglitazone has a direct effect on ovarian steroidogenesis, we studied the effect of troglitazone on androgen production in cultured rat theca interstitial cells (rTICs) and on progesterone production in cultured human granulosa lutein cells (hGLCs).
METHODS: Primary cell cultures of rTICs were isolated from the ovaries of hypophysectomized immature Sprague-Dawley rats, and hGLCs was obtained from women who had in vitro fertilization-embryo transfer. Treatments included troglitazone, insulin, LH, hCG, and combinations of these agents. Media were collected and assayed for androsterone and progesterone.
RESULTS: Troglitazone decreased both basal and insulin-, LH-, and hCG-stimulated androsterone production by TIC and progesterone production by hGLCs in a dose-dependent manner.
CONCLUSION: We found a direct effect of troglitazone on the production of androsterone by rTICs and progesterone by hGLCs. These results suggest that the beneficial effects of troglitazone in PCOS may not be due solely to improvement of peripheral insulin resistance and hyperinsulinemia, but also to a possible direct effect on ovarian steroidogenesis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12009391

Source DB:  PubMed          Journal:  J Soc Gynecol Investig        ISSN: 1071-5576


  5 in total

1.  Genetic variants in peroxisome proliferator-activated receptor gamma influence insulin resistance and testosterone levels in normal women, but not those with polycystic ovary syndrome.

Authors:  Heath J Antoine; Marita Pall; Belynda C Trader; Yii-Der I Chen; Ricardo Azziz; Mark O Goodarzi
Journal:  Fertil Steril       Date:  2006-12-04       Impact factor: 7.329

Review 2.  Endocrinological actions of Unkei-to, a herbal medicine, and its clinical usefulness in anovulatory and/or infertile women.

Authors:  Takahisa Ushiroyama
Journal:  Reprod Med Biol       Date:  2003-04-30

3.  Meal intake similarly reduces circulating concentrations of octanoyl and total ghrelin in humans.

Authors:  P Lucidi; G Murdolo; C Di Loreto; N Parlanti; A De Cicco; A Ranchelli; C Fatone; C Taglioni; C Fanelli; F Santeusanio; P De Feo
Journal:  J Endocrinol Invest       Date:  2004-05       Impact factor: 4.256

4.  Decreased androgen levels and improved menstrual pattern after angiotensin II receptor antagonist telmisartan treatment in four hypertensive patients with polycystic ovary syndrome: case series.

Authors:  Mojca Jensterle; Andrej Janez; Bojan Vrtovec; Helena Meden-Vrtovec; Marija Pfeifer; Janez Prezelj; Tomaz Kocjan
Journal:  Croat Med J       Date:  2007-12       Impact factor: 1.351

5.  Effect of troglitazone on the excess testosterone and LH secretion in thyroidectomized, insulin-resistant, type 2 diabetic Goto-Kakizaki rats.

Authors:  Mayumi Matsushita; Kazuhiro Tamura; Shingo Osada; Hiroshi Kogo
Journal:  Endocrine       Date:  2005-08       Impact factor: 3.925

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.